Calidi Biotherapeutics announced the presentation of new data detailing the molecular mechanisms of action underlying the immunomodulatory role of Calidi’s therapies at the American Association for Cancer Research Annual, AACR, Meeting 2024, in San Diego, California. The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session. “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads. We believe this novel approach using allogeneic stem cells differentiates our technology and offers the potential of our platforms, CLD-101 and CLD-201, to serve as universal, off-the-shelf, options for patients needing improved therapeutic outcomes in their treatments for cancer,” said Allan Camaisa, CEO and Chairman of the Board at Calidi Biotherapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi price target lowered to $4.50 from $9 at Baird
- Calidi price target lowered to $2 from $11 at H.C. Wainwright
- Calidi Biotherapeutics Issues Regulation FD Disclosure Notice
- Calidi Biotherapeutics Restructures Debt and Streamlines Finances
- Calidi Biotherapeutics Showcases Oncolytic Virotherapy Advances